LitCovid-sample-Enju  

PMC:7205724 / 0-362 JSONTXT 15 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T0 0-7 IN denotes Towards
T1 8-17 NN denotes treatment
T2 18-26 NN denotes planning
T3 27-29 IN denotes of
T4 30-38 NN denotes COVID-19
T5 38-39 -COLON- denotes :
T6 40-49 NN denotes Rationale
T7 50-53 CC denotes and
T8 54-64 NN denotes hypothesis
T9 65-68 IN denotes for
T10 69-72 DT denotes the
T11 73-76 NN denotes use
T12 77-79 IN denotes of
T13 80-88 JJ denotes multiple
T14 89-106 JJ denotes immunosuppressive
T15 107-113 NNS denotes agents
T16 113-114 -COLON- denotes :
T17 115-130 NNS denotes Anti-antibodies
T18 130-131 -COMMA- denotes ,
T19 132-147 NNS denotes immunoglobulins
T20 147-148 -COMMA- denotes ,
T21 149-152 CC denotes and
T22 153-168 NNS denotes corticosteroids
T23 170-180 NNS denotes Highlights
T24 181-182 IN denotes •
T25 184-188 NNP denotes IVIG
T26 188-189 -COMMA- denotes ,
T27 190-198 VBN denotes combined
T28 199-203 IN denotes with
T29 204-217 NN denotes moderate-dose
T30 218-220 IN denotes of
T31 221-236 NNS denotes corticosteroids
T32 236-237 -COMMA- denotes ,
T33 238-243 MD denotes might
T34 244-251 VB denotes improve
T35 252-259 NN denotes patient
T36 260-268 NNS denotes outcomes
T37 270-271 PDT denotes •
T38 273-276 DT denotes The
T39 277-280 NN denotes use
T40 281-283 IN denotes of
T41 284-299 NNS denotes corticosteroids
T42 300-305 MD denotes might
T43 306-316 VB denotes accelerate
T44 317-325 NN denotes recovery
T45 326-330 IN denotes from
T46 331-339 NN denotes COVID-19
T47 341-342 PDT denotes •
T48 344-346 DT denotes No
T49 347-357 VBN denotes controlled
R0 T2 T0 arg2Of planning,Towards
R1 T2 T1 arg1Of planning,treatment
R10 T11 T12 arg1Of use,of
R11 T15 T12 arg2Of agents,of
R12 T15 T13 arg1Of agents,multiple
R13 T15 T14 arg1Of agents,immunosuppressive
R14 T7 T16 arg1Of and,:
R15 T17 T18 arg1Of Anti-antibodies,","
R16 T19 T18 arg2Of immunoglobulins,","
R17 T21 T20 arg1Of and,","
R18 T18 T21 arg1Of ",",and
R19 T22 T21 arg2Of corticosteroids,and
R2 T2 T3 arg1Of planning,of
R20 T25 T24 arg1Of IVIG,•
R21 T25 T26 arg1Of IVIG,","
R22 T25 T27 arg2Of IVIG,combined
R23 T27 T28 arg1Of combined,with
R24 T29 T28 arg2Of moderate-dose,with
R25 T29 T30 arg1Of moderate-dose,of
R26 T31 T30 arg2Of corticosteroids,of
R27 T34 T32 arg1Of improve,","
R28 T25 T33 arg1Of IVIG,might
R29 T34 T33 arg2Of improve,might
R3 T4 T3 arg2Of COVID-19,of
R30 T25 T34 arg1Of IVIG,improve
R31 T36 T34 arg2Of outcomes,improve
R32 T36 T35 arg1Of outcomes,patient
R33 T39 T37 arg1Of use,•
R34 T39 T38 arg1Of use,The
R35 T39 T40 arg1Of use,of
R36 T41 T40 arg2Of corticosteroids,of
R37 T39 T42 arg1Of use,might
R38 T43 T42 arg2Of accelerate,might
R39 T39 T43 arg1Of use,accelerate
R4 T2 T5 arg1Of planning,:
R40 T44 T43 arg2Of recovery,accelerate
R41 T44 T45 arg1Of recovery,from
R42 T46 T45 arg2Of COVID-19,from
R5 T6 T7 arg1Of Rationale,and
R6 T8 T7 arg2Of hypothesis,and
R7 T7 T9 arg1Of and,for
R8 T11 T9 arg2Of use,for
R9 T11 T10 arg1Of use,the